Clinical trials: Radiation Effects
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.
Head and Neck Neoplasms, Mucositis
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral…
- Trial name
- Brilacidin (NCT02324335)
- Testing
- Brilacidin
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Glioblastoma Multiforme
UNITE Study: Understanding New Interventions With GBM ThErapy
The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor…
- Trial name
- NCT03419403
- Testing
- Steroid eye drops, Vasoconstrictor eye drops, Cold compress
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer
This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer.
- Trial name
- NCT01363986
- Testing
- trastuzumab [Herceptin]
- Where
- 16 sites in Italy
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin
This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind…
- Trial name
- NCT00386100
- Testing
- Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd)
- Where
- 116 sites in United States, Argentina and 7 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
- Trial name
- NCT00679939
- Testing
- Rosiglitazone, Metformin
- Where
- 42 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Oral Mucositis
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients…
- Trial name
- NCT03689712
- Testing
- GC4419 90mg
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 455 people
- Sponsor
- Galera Therapeutics, Inc.
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Colorectal Cancer
A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer
This single arm study will assess the efficacy and safety of treatment with Xeloda plus standard pelvic radiotherapy in participants with locally advanced rectal cancer.
- Trial name
- NCT00796718
- Testing
- Standard radiotherapy, Capecitabine [Xeloda]
- Where
- 2 sites in Slovakia
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with…
- Trial name
- NCT01227707
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], Radiation therapy
- Where
- 9 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine…
- Trial name
- NCT00439244
- Testing
- Zoledronic acid, Teriparatide
- Where
- 33 sites in United States, Belgium and 2 more
- Volunteers
- 412 people
- Sponsor
- Novartis
Rectal Cancer
Tecemotide (L-BLP25) in Rectal Cancer
The objective of this mechanistic study is to determine the impact of tecemotide (L-BLP25) administration on the mucinous glycoprotein 1 - (MUC1) specific immune response in subjects with newly diagnosed rectal cancer who are…
- Trial name
- SPRINT (NCT01507103)
- Testing
- Tecemotide (L-BLP25), cyclophosphamide (CPA), Chemoradiotherapy
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Osteogenesis Imperfecta
Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
This is a prospective, multicenter, single-arm study in children 2 to 17 years of age with OI to evaluate efficacy and safety of denosumab.
- Trial name
- OI (NCT02352753)
- Testing
- Denosumab
- Where
- 49 sites in United States, Australia and 11 more
- Volunteers
- 153 people
- Sponsor
- Amgen
Back Pain Without Radiation
Duloxetine Versus Placebo in Chronic Low Back Pain
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
- Trial name
- NCT00424593
- Testing
- Duloxetine
- Where
- 17 sites in Brazil, France and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company